NEW HAVEN, Conn., Aug. 5, 2020 /PRNewswire/ -- Biohaven
Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a
commercial-stage biopharmaceutical company with a portfolio of
innovative, late-stage product candidates targeting neurological
and neuropsychiatric diseases, will hold its upcoming second
quarter 2020 earnings call and webcast, reporting financial results
for the quarter ended June 30, 2020
and providing a review of recent accomplishments and anticipated
upcoming milestones, on Monday, August 10,
2020 at 8:00 a.m. ET.
To access the call, please dial 877-407-9120 (domestic) or
412-902-1009 (international). The conference call webcast, and
accompanying slide presentation, can be accessed through the
"Investors" section of Biohaven's website at www.biohavenpharma.com
. To ensure a timely connection, it is recommended that
participants register at least 15 minutes prior to the scheduled
webcast. A replay of the call will be made available for two weeks
following the conference call. To hear a replay of the call, dial
877-660-6853 (domestic) or 201-612-7415 (international) with
conference ID 13707340. An archived webcast will be available on
Biohaven's website.
About Biohaven
Biohaven is a commercial-stage
biopharmaceutical company with a portfolio of innovative,
best-in-class therapies to improve the lives of patients with
debilitating neurological and neuropsychiatric diseases, including
rare disorders. Biohaven's neuroinnovation portfolio includes
FDA-approved NURTEC™ ODT (rimegepant) for the acute treatment of
migraine and a broad pipeline of late-stage product candidates
across three distinct mechanistic platforms: CGRP receptor
antagonism for the acute and preventive treatment of migraine;
glutamate modulation for obsessive-compulsive disorder, Alzheimer's
disease, and spinocerebellar ataxia; and myeloperoxidase (MPO)
inhibition for multiple system atrophy and amyotrophic lateral
sclerosis. More information about Biohaven is available at
www.biohavenpharma.com.
Biohaven Contact:
Dr. Vlad Coric
Chief Executive Officer
Vlad.Coric@biohavenpharma.com
NURTEC is a trademark of Biohaven Pharmaceutical Holding Company
Ltd.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biohaven-pharmaceutical-to-report-second-quarter-2020-financial-results-and-recent-business-developments-on-august-10-2020-301106892.html
SOURCE Biohaven Pharmaceutical Holding Company Ltd.